Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme

被引:0
作者
Isabelle Krummenacher
Brenda Spencer
Sophie Du Pasquier
Olivier Bugnon
Matthias Cavassini
Marie P. Schneider
机构
[1] University of Geneva,Community Pharmacy, School of Pharmaceutical Sciences
[2] University of Lausanne,Institute of Social and Preventive Medicine (IUMSP)
[3] Lausanne University Hospital,Community Pharmacy, Department of Ambulatory Care and Community Medicine
[4] University of Lausanne,Service of Infectious Disease
[5] Centre Hospitalier Universitaire Vaudois and University of Lausanne,Community Pharmacy
[6] Pharmacie de la Policlinique Médicale Universitaire,undefined
来源
International Journal of Clinical Pharmacy | 2014年 / 36卷
关键词
HIV; Interdisciplinarity; Intervention; Medication adherence; Pharmacists; Qualitative research; Switzerland;
D O I
暂无
中图分类号
学科分类号
摘要
Background Medication adherence is a complex, dynamic and changing behaviour that is affected by a variety of factors, including the patient’s beliefs and life circumstances. Studies have highlighted barriers to medication adherence (e.g., unmanaged side effects or a lack of social support), as well as facilitators of medication adherence (e.g., technical simplicity of treatment and psychological acceptance of the disease). Since August 2004, in Lausanne (Switzerland), physicians have referred patients who are either experiencing or are at risk of experiencing problems with their HIV antiretroviral treatment (ART) to a routine interdisciplinary ART adherence programme. This programme consists of multifactorial intervention including electronic drug monitoring (MEMSTM). Objective This study’s objective was to identify the barriers and facilitators encountered by HIV patients with suboptimal medication adherence (≤90 % adherence over the study period). Setting The community pharmacy of the Department of Ambulatory Care and Community Medicine in Lausanne (Switzerland). Method The study consisted of a retrospective, qualitative, thematic content analysis of pharmacists’ notes that were taken during semi-structured interviews with patients and conducted as part of the ART adherence programme between August 2004 and May 2008. Main outcome measure Barriers and facilitators encountered by HIV patients. Results Barriers to and facilitators of adherence were identified for the 17 included patients. These factors fell into three main categories: (1) cognitive, emotional and motivational; (2) environmental, organisational and social; and (3) treatment and disease. Conclusion The pharmacists’ notes revealed that diverse barriers and facilitators were discussed during medication adherence interviews. Indeed, the results showed that the 17 non-adherent patients encountered barriers and benefited from facilitators. Therefore, pharmacists should inquire about all factors, regardless of whether they have a negative or a positive impact on medication adherence, and should consider all dimensions of patient adherence. The simultaneous strengthening of facilitators and better management of barriers may allow healthcare providers to tailor care to a patient’s specific needs and support each individual patient in improving his medication-related behaviour.
引用
收藏
页码:716 / 724
页数:8
相关论文
共 50 条
  • [21] A qualitative analysis of the barriers and facilitators of HIV counselling and testing perceived by adolescents in South Africa
    Strauss, Michael
    Rhodes, Bruce
    George, Gavin
    BMC HEALTH SERVICES RESEARCH, 2015, 15
  • [22] A qualitative analysis of the barriers and facilitators of HIV counselling and testing perceived by adolescents in South Africa
    Michael Strauss
    Bruce Rhodes
    Gavin George
    BMC Health Services Research, 15 (1)
  • [23] Barriers and facilitators of ART adherence in Hawassa town, Southern Ethiopia: A grounded theory approach
    Wondiye, Habtamu
    Fentahun, Netsanet
    Limaye, Rupali J.
    Kote, Mesfin
    Girma, Eshetu
    Ethiopian Journal of Health Development, 2016, 30 (02) : 66 - 77
  • [24] A Social-Ecological View of Barriers and Facilitators for HIV Treatment Adherence: Interviews with Puerto Rican HIV Patients
    Castro, Eida M.
    Santiago, Lydia E.
    Jimenez, Julio C.
    Davila-Vargas, Daira
    Rosal, Milagros C.
    PLOS ONE, 2015, 10 (09):
  • [25] Facilitators and Barriers of Adherence to Multi-Disease Exacerbation Action Plans in COPD Patients - A Qualitative Study
    Schrijver, J.
    Effing, T.
    Brusse-Keizer, M.
    van der Palen, J.
    van der Valk, P.
    Lenferink, A.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 20 (01) : 262 - 273
  • [26] Barriers and facilitators of antiretroviral therapy (ART) adherence habit formation in Sub-Saharan Africa: Evidence from a qualitative study in Kampala, Uganda
    Stecher, Chad
    Palimaru, Alina I.
    Odiit, Mary
    Lunkuse, Lillian
    Walukaga, Stewart
    Linnemayr, Sebastian
    SOCIAL SCIENCE & MEDICINE, 2023, 317
  • [27] Facilitators of medication adherence in patients with hypertension: a qualitative study
    Nasab, Zahra Ghaderi
    Sharifi, Hamid
    Shahrbabaki, Parvin Mangolian
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [28] Adherence to Pulmonary Rehabilitation in COPD A QUALITATIVE EXPLORATION OF PATIENT PERSPECTIVES ON BARRIERS AND FACILITATORS
    Oates, Gabriela R.
    Niranjan, Soumya J.
    Ott, Corilyn
    Scarinci, Isabel C.
    Schumann, Christopher
    Parekh, Trisha
    Dransfield, Mark T.
    JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION, 2019, 39 (05) : 344 - 349
  • [29] Barriers and facilitators of adherence to treatment among women with vulvovaginal candidiasis: a qualitative study
    Maryam Erfaninejad
    Arash Salahshouri
    Nasrin Amirrajab
    European Journal of Medical Research, 27
  • [30] Barriers and facilitators for patients' acceptance and adherence to auriculotherapy: A qualitative systematic review using the theoretical domains framework
    Zhang, Ying
    Li, Kun
    Wu, Siyuan
    Zhu, Keping
    Xie, Fuchao
    Zhu, Binbin
    Wang, Lijun
    Wang, Wei
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2025, 25 (01)